BioSpace News Archive

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in September

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.

Orchard Therapeutics, a global gene therapy leader, announced that the Compensation Committee of Orchard’s Board of Directors approved the grant of non-statutory stock options to four new employees to purchase an aggregate of 278,500 ordinary shares under Orchard’s 2020 Inducement Equity Plan.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat passages and other diseased tissues, announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.

uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced its participation in the following upcoming investor and scientific conferences.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of September.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced positive interim results from a Phase 2a positron emission tomography imaging-based clinical trial of PLN-74809, an oral small molecule dual selective inhibitor of αvβ6/αvβ1, in patients with idiopathic pulmonary fibrosis.

Akari Therapeutics, Plc announced that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.